DexCom (DXCM) Stock Forecast & Price Target

Q: What analysts cover DexCom?

DexCom has been rated by research analysts at Argus , Benchmark , BTIG Research , Canaccord Genuity Group , Citigroup , Deutsche Bank Aktiengesellschaft , JPMorgan Chase & Co. , Mizuho , Piper Sandler , Raymond James Financial , Robert W. Baird , Royal Bank Of Canada , Stifel Nicolaus , TD Cowen , Truist Financial , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$84.41 +0.53 (+0.64%)

As of 03:43 PM Eastern

Compare

DexCom - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
2

Buy
23

Based on 26 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 2 have given a hold rating, 21 have given a buy rating, and 2 have given a strong buy rating for DXCM.

Consensus Price Target

$88.71
5.09% Upside

According to the 26 analysts' twelve-month price targets for DexCom, the average price target is $88.71. The highest price target for DXCM is $105.00, while the lowest price target for DXCM is $64.00. The average price target represents a forecasted upside of 5.09% from the current price of $84.41.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXCM Analyst Ratings Over Time

Type	Current Forecast 9/10/25 to 9/10/26	1 Month Ago 8/11/25 to 8/11/26	3 Months Ago 6/12/25 to 6/12/26	1 Year Ago 9/10/24 to 9/10/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	21 Buy rating(s)	21 Buy rating(s)	19 Buy rating(s)	14 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$88.71	$88.71	$84.29	$99.89
Forecasted Upside	5.09% Upside	-0.92% Downside	11.84% Upside	31.44% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Healthcare Companies	Broader Market
Consensus Rating Score	2.92	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	5.86% Upside	952.09% Upside	17.22% Upside
News Sentiment Rating	Positive News See Recent DXCM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/11/2026	Weiss Ratings 5 of 5 stars		Upgrade	Hold (C-) ➝ Hold (C)
8/4/2026	Argus 3 of 5 stars	Steve Silver Not Rated	Boost Target	Buy	$86.00 ➝ $96.00	+11.08%
8/3/2026	Canaccord Genuity Group 3 of 5 stars	William Plovanic 2 of 5 stars	Set Target	Buy	$82.00 ➝ $90.00	+3.60%
7/31/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Strong-Buy	$94.00	+11.54%
7/31/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$88.00 ➝ $95.00	+27.45%
7/31/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$105.00	+24.59%
7/31/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$84.00 ➝ $88.00	+18.06%
7/31/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$80.00 ➝ $90.00	+20.74%
7/31/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$87.00 ➝ $93.00	+24.77%
Bezos… DOOMED (Ad) A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. Watch James Altucher's free video breakdown before the September 25 deadline.
7/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$90.00 ➝ $95.00	+27.45%
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kendall Au Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$85.00 ➝ $90.00	+7.49%
7/31/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$90.00 ➝ $95.00	+14.08%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$65.00 ➝ $82.00	-1.32%
7/31/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$85.00 ➝ $90.00	+10.34%
7/31/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Jackson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$77.00 ➝ $82.00	-0.33%
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$96.00	+26.92%
6/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kieran Ryan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$86.00	+24.51%
5/18/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underweight	$67.00 ➝ $64.00	+3.85%
5/18/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$100.00 ➝ $80.00	+24.53%
5/15/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$77.00	+25.35%
3/24/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$90.00	+36.49%
1/12/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight
12/16/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$92.00	+39.97%
10/1/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kate McShane Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$104.00 ➝ $89.00	+37.98%
9/8/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Lichtman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	T. Perez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
2/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Issie Kirby Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$85.00 ➝ $115.00	+32.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:43 PM ET.

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 9, 2026. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

DexCom, Inc. recently reported strong second-quarter financial results, beating analyst expectations with earnings per share of $0.70 against a consensus estimate of $0.61, while revenue of $1.31 billion exceeded the projected $1.29 billion, demonstrating robust demand for its continuous glucose monitoring systems.
The company has received significant institutional support, with the Saudi Central Bank increasing its holdings by 87.1% in the second quarter and the Virginia Retirement Systems establishing a new position worth approximately $36.28 million, indicating growing confidence among major global investors.
Wall Street analysts maintain a positive outlook, with a consensus rating of Moderate Buy and a price target of $88.71, which suggests potential upside from the current stock price of $83.88, supported by recent upgrades from firms like Piper Sandler and Royal Bank of Canada.
DexCom, Inc. continues to show strong year-over-year growth, with quarterly revenue increasing by 13.1% and net margins reaching 20.12%, reflecting the company's ability to expand its market share in the diabetes care sector while maintaining profitability.
The stock has demonstrated strong momentum, hitting a 52-week high of $92.59 in August 2026, which is significantly above its 52-week low of $54.11, suggesting that the market is increasingly valuing the company's long-term growth potential and product innovation.

DexCom
Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

There is a notable trend of insider selling, with executives such as Kevin Sayer and Sadie Stern selling significant portions of their holdings in the last three months, which may signal that company insiders are taking advantage of the recent stock price appreciation to reduce their personal exposure.
The company's valuation is relatively high, with a price-to-earnings ratio of 33.15, which may limit further upside potential if growth slows or if the broader market becomes more sensitive to valuation multiples in the healthcare sector.
DexCom, Inc. carries a beta of 1.42, indicating that its stock is more volatile than the overall market, which could lead to larger price swings and higher risk for investors who are sensitive to market fluctuations.
Short interest has been increasing in recent months, with shares shorted rising to 16.5 million as of August 2026, suggesting that some market participants are betting against the stock's future performance, which could create downward pressure on the price.
The company does not pay a dividend, with a yield of 0.00%, which may be a drawback for income-focused investors who prefer stocks that provide regular cash flow in addition to capital appreciation.

DXCM Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $88.71, with a high forecast of $105.00 and a low forecast of $64.00.

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There is currently 1 sell rating, 2 hold ratings, 21 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DXCM shares.

According to analysts, DexCom's stock has a predicted upside of 5.09% based on their 12-month stock forecasts.

Over the previous 90 days, DexCom's stock had 2 upgrades and 1 downgrade by analysts.

DexCom has been rated by research analysts at Argus, Benchmark, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Mizuho, Piper Sandler, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like DexCom more than other "healthcare" companies. The consensus rating for DexCom is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how DXCM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With DexCom Recommendations

MarketBeat monitors more than a dozen sources for DexCom analyst ratings, with the most recent rating issued on 8/11/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Stock Forecast & Price Target